Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Advanced Liver Cancer
ConditionLiver Cancer
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-70
SponsorZhiyong Huang
About this trial
Single-arm, open-label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocytes (TIL) infusion followed by IL-2 after a non-myeloablative(NMA) lymphodepletion preparative regimen for the treatment of patients with advanced liver cancer.
Eligibility criteria
Qualifiers
The subjects must be informed of the study before the test and voluntarily sign a written informed consent.
Age of the patients was between 18~70 years
Eligible patients have histologically proven advanced liver cancer
Eastern Cooperative Oncology Group (ECOG) performance status was 0-1
Disqualifiers
With previous or concurrent other active cancer (except carcinoma in situ that has been cured without onset within 5 years, or those that can be cured by adequate treatment)
Patients with metastasis to Central Nervous System or brain
Have received organ transplantation in the past
Received major liver surgery within 4 weeks before the first administration (except liver metastases biopsy).
Trial design
Treatments tested in this trial
- Autologous Tumor Infiltrating Lymphocytes
Treatment groups
16 Participants
are divided into 1 treatment groupSponsors and collaborators
Zhiyong Huang
Lead sponsor
Tongji Hospital
Sponsor institution
Wuhan Elongevity Technology Co., Ltd.
Collaborator
Source ClinicalTrials.gov